8-K filed Nov 16, 2026 at 09:15 ET
Jaguar Health reported Q3 2026 total revenue of $2.3M, down 24% YoY from $3.1M, driven by an 82% decline in product revenue to $0.55M after licensing U.S. commercial rights to Future Pak. Net loss narrowed 40% to $5.8M from $9.6M, and the company reduced debt by $10.1M via a stock-for-debt exchange with Streeterville. A planned NDA filing for crofelemer in MVID in mid-2027 provides a long-term catalyst, but the revenue decline and extreme dilution risk from a $75M ATM program (15x market cap) dominate the near-term outlook.